BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (JULY AUGUST 2020)

Experimental Treatment of Hemolytic Disease of Newborns and Inhibition of Hemolysis

Nina Іvanova

Introduction: Original structure and technology of the liposomal antihemolytic preparation AmiF on the basis of natural lipids has been developed for treatment of diseases connected with hemolysis and also for treatment hemolytic disease of newborns and for inhibition immune hemolysis, caused hemoglobinuria paroxysmalis nocturna. Also AmiF prevents hemolysis caused by the action of some medicine. We discovered that our liposomal preparation stabilizes of the erythrocyte membrane. This it can also be used to protect red blood cells during viral damage by COVID- 19.

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.